Compounds 1–13 and 16–26 exhibited moderate inhibitory activities against phosphodiesterase-4 (PDE4), a drug target for asthma and chronic obstructive pulmonary disease, with IC50 values in the range of 1.34–7.26 μM. Here, PDE4A is linked to asthma.